✦ LIBER ✦

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

✍ Scribed by Axel Glasmacher; Corinna Hahn; Florian Hoffmann; Ralph Naumann; Hartmut Goldschmidt; Marie von Lilienfeld-Toal; Katjana Orlopp; Ingo Schmidt-Wolf; Marcus Gorschlüter

Book ID: 108673590
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 181 KB
Volume: 132
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2005.05914.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase II and pharmacokinetic study of th

Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma

✍ Hirokazu Murakami; Kazuyuki Shimizu; Morio Sawamura; Kenshi Suzuki; Isamu Sugiur 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 207 KB

Combined thalidomide and cyclophosphamid

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study

✍ Sjoerd Hovenga; Simon M. G. J. Daenen; Joost T. M. de Wolf; Gustaaf W. van Imhof 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

Phase 2 study of arsenic trioxide in pat

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Phase II randomized trial of bevacizumab

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

✍ George Somlo; Ashkan Lashkari; William Bellamy; Todd M. Zimmerman; Joseph M. Tus 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB